Phaseline

Companies › Draig Therapeutics

Draig Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Psychiatry; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DT-101–Phase 2Major Depressive Disorder (MDD)May 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07610473DT-101Phase 2Major Depressive Disorder (MDD)PsychiatryMay 2027
NCT07300969DT-101Phase 2Major Depressive Disorder (MDD)PsychiatryAug 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Kadence Bio HB BioTech Beckley Psytech Synendos Therapeutics Neuroventi

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.